Snapshot · The Peter Attia Drive
CISNet's 2024 analysis found annual screening reduces breast cancer mortality by 42% versus 30% for biennial — translating to 230 vs 165 life-years gained per 1,000 women.
Where this was said
At 32:15 · chapter starts 30:15
The debate between annual and biennial mammography is one of the most consequential and most misunderstood in preventive medicine. Peter Attia starts by acknowledging an important evidentiary gap: no randomised controlled trial has ever directly compared the two intervals with mortality as its primary endpoint. Every recommendation rests on modelling studies and observational data. The most important models come from CISNet, commissioned three times by the USPSTF. Counterintuitively, the same CISNet data that the USPSTF used to justify biennial screening have been interpreted by other major cancer and radiology groups as supporting annual screening. The resolution lies in understanding which question is being asked. The USPSTF asked: what gives the best population-level trade-off between benefit, cost, and false positives? The answer to that question may indeed be biennial. But if the question is what gives an individual woman the best chance of not dying from breast cancer, CISNet's 2024 comprehensive analysis — which incorporated both 2D digital mammography and DBT — answers clearly: annual screening of women aged 40–79 produced a 42% mortality reduction versus 30% for biennial, corresponding to 230 versus 165 life-years gained per 1,000 women [1] — Peter Attia "Annual vs biennial: 42% vs 30% mortality reduction: CISNet's 2024 analysis found annual screening reduces breast cancer mortality by 42% ve…" 32:15 . Importantly, while annual screening produces more cumulative false positives, the per-exam false positive rate is actually lower for annual screeners, likely because radiologists have a more recent baseline image for comparison. Observational data reinforce the models: annual screeners had an interval cancer rate of 11% versus 38% for biennial screeners, and 76% versus 56% stage 1 diagnosis rates [2] — Peter Attia "Interval cancers: 11% annual vs 38% biennial: Among women with breast cancer aged 40–84, annual screeners had far fewer interval cancers (1…" 33:30 . Attia's verdict is unambiguous: 'If your goal is to maximize your chances of avoiding death from breast cancer as an individual, annual mammography is the better strategy.'
CISNet's own 2024 models show annual screening reduces breast cancer mortality by 42% versus 30% for biennial — 230 life-years gained per 1,000 women versus 165. The biennial recommendation was built for population budgets, not individual survival.
Among real women with breast cancer, annual screeners had an 11% interval cancer rate versus 38% for biennial screeners, and a 76% versus 56% rate of stage 1 diagnosis. These are not marginal differences — they are survival-relevant.
Among women with breast cancer aged 40–84, annual screeners had far fewer interval cancers (11%) versus biennial screeners (38%), and were more likely to have stage 1 diagnoses.
Mental health challenges are nearly universal — BetterHelp's own research found the majority of Americans experiencing symptoms right now.
When applying for Medicaid to cover nursing home costs, there is a 5-year look-back period that can disqualify applicants who gave away or spent down assets.
A broken pipe filled the Bad Friends studio with what the hosts identified as hydrogen sulfide — microscopic fecal aeroparticles — that the crew denied smelling.
Fei-Fei Li's father's liver surgery performed by a da Vinci robot resulted in 10 times less blood loss than a typical open liver surgery, thanks to laparoscopic precision.
Approximately 115 million adults in the US currently have prediabetes, most of whom are unaware, according to the Lingo sponsor segment.
Drug overdose deaths in the US fell from 110,000 to 80,000 in 2024, and then to roughly 70,000 — the largest single-year drop the CDC has ever recorded.
Men's overdose death rate fell 27% in a single year, outpacing the 23% drop for women.
The steepest decline in overdose deaths was among 15–24-year-olds, whose rate fell 37%.
Fei-Fei Li observed that on a given hospital shift, nurses walk miles just to fetch medicine and supplies, illustrating a clear use case for assistive robotics in healthcare.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.